Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Productivity losses and public finance burden attributable to breast cancer in Poland, 2010–2014

Authors: Błażej Łyszczarz, Ewelina Nojszewska

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Apart from the health and social burden of the disease, breast cancer (BC) has important economic implications for the sick, health system and whole economy. There has been a growing interest in the economic aspects of breast cancer and analyses of the disease costs seem to be the most explored topic. However, the results from these studies are hardly comparable. With this study we aim to contribute to the field by providing estimates of productivity losses and public finance burden attributable to BC in Poland.

Methods

We used retrospective prevalence-based top-down approach to estimate the productivity losses (indirect costs) of BC in Poland in the period 2010–2014. Human capital method (HCM) and societal perspective were used to estimate the costs of: absenteeism of the sick and caregivers, presenteeism of the sick and caregivers, disability, and premature mortality. We also used figures illustrating public finance burden attributable to the disease. Deterministic sensitivity analysis was performed to assess the stability of the estimates. A variety of data sources were used with the social insurance system and Polish National Cancer Registry being the most important ones.

Results

Productivity losses associated with BC in Poland were €583.7 million in 2010 and they increased to €699.7 million in 2014. Throughout the period these costs accounted for 0.162–0.171% of GDP, an equivalent of 62,531–65,816 per capita GDP. Losses attributable to disability and premature mortality proved to be the major cost drivers with 27.6%–30.6% and 22.0%–24.6% of the total costs respectively. The costs due to caregivers’ presenteeism were negligible (0.1% of total costs). Public finance expenditure for social insurance benefits to BC sufferers ranged from €50.2 million (2010) to €56.6 million (2014), an equivalent of 0.72–0.79% of expenditures for all diseases. Potential losses in public finance revenues accounted for €173.9 million in 2010 and €211.0 million in 2014. Sensitivity analysis showed that the results were robust to changes in the model parameters.

Conclusions

The productivity losses attributable to BC in Poland were a sizable burden for the society. They contributed both to decreased economy output and to public finance deficit.
Footnotes
1
The age group 15–59 years does not strictly correspond to the productive age of women in Poland (18–59 years); the age interval used is determined by the way that the Polish National Cancer Registry reports the age-specific data. Nevertheless, accounting for the age distribution of BC, we can expect that both populations are practically the same.
 
2
Following [24] we assumed that a person partially incapable to work is able to work with 0.25 productivity of a healthy person; this assumption is based on the fact that the value of benefit received in this case is 0.75 of the benefit received by a person completely incapable to work.
 
3
In 2014 these four taxes contributed to 89% of state budget revenues.
 
4
Social pension is a benefit which is payable to an adult who has been recognised as completely incapable of work due to impairment of body functions which occurred before reaching the age of 18 years.
 
Literature
1.
go back to reference Didkowska J, Olasek P, Czauderna K, Wojciechowska U. Cancer in Poland in 2014. Warsaw: the M. Skłodowska-curie memorial cancer center and institute of. Oncology. 2016; Didkowska J, Olasek P, Czauderna K, Wojciechowska U. Cancer in Poland in 2014. Warsaw: the M. Skłodowska-curie memorial cancer center and institute of. Oncology. 2016;
3.
go back to reference Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRefPubMed Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRefPubMed
4.
go back to reference Sant M, Chirlaque Lopez MD, Agresti R, Sánchez Pérez MJ, Holleczek B, Bielska-Lasota M, Dimitrova N, Innos K, Katalinic A, Langseth H, Larrañaga N, Rossi S, Siesling S, Minicozzi P, The EUROCARE-5 Working Group. Survival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EUROCARE-5 study. Eur J Cancer. 2015;51:2191–205.CrossRefPubMed Sant M, Chirlaque Lopez MD, Agresti R, Sánchez Pérez MJ, Holleczek B, Bielska-Lasota M, Dimitrova N, Innos K, Katalinic A, Langseth H, Larrañaga N, Rossi S, Siesling S, Minicozzi P, The EUROCARE-5 Working Group. Survival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EUROCARE-5 study. Eur J Cancer. 2015;51:2191–205.CrossRefPubMed
5.
go back to reference Smaga A, Mikułowska M, Komorowska A, Falkiewicz B, Gryglewicz J. Rak piersi w Polsce - leczenie to inwestycja [breast cancer in Poland – treatment is an investment]. Warsaw: Sequence; 2014. Smaga A, Mikułowska M, Komorowska A, Falkiewicz B, Gryglewicz J. Rak piersi w Polsce - leczenie to inwestycja [breast cancer in Poland – treatment is an investment]. Warsaw: Sequence; 2014.
6.
go back to reference Kozierkiewicz A, Śliwczyński A, Pakulski M, Jassem J. Wydatki na leczenie raka piersi w Polsce [breast cancer treatment expenditures in Poland]. Nowotwory. 2013;63:217–26.CrossRef Kozierkiewicz A, Śliwczyński A, Pakulski M, Jassem J. Wydatki na leczenie raka piersi w Polsce [breast cancer treatment expenditures in Poland]. Nowotwory. 2013;63:217–26.CrossRef
7.
go back to reference Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004;83:25–32.CrossRefPubMed Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004;83:25–32.CrossRefPubMed
8.
go back to reference Barron JJ, Quimbo R, Nikam PT, Amonkar MM. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat. 2008;109:367–77.CrossRefPubMed Barron JJ, Quimbo R, Nikam PT, Amonkar MM. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat. 2008;109:367–77.CrossRefPubMed
9.
go back to reference Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health. 2000;3:23–30.CrossRefPubMed Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health. 2000;3:23–30.CrossRefPubMed
10.
go back to reference Khanna R, Madhavan SS, Bhanegaonkar A, Remick SC. Prevalence, healthcare utilization, and costs of breast cancer in a state Medicaid fee-for-service program. J Women's Health. 2011;20:739–47.CrossRef Khanna R, Madhavan SS, Bhanegaonkar A, Remick SC. Prevalence, healthcare utilization, and costs of breast cancer in a state Medicaid fee-for-service program. J Women's Health. 2011;20:739–47.CrossRef
11.
go back to reference Lamerato L, Havstad S, Gandhi S, Jones D, Nathanson D. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer. 2006;106:1875–82.CrossRefPubMed Lamerato L, Havstad S, Gandhi S, Jones D, Nathanson D. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer. 2006;106:1875–82.CrossRefPubMed
12.
go back to reference Gruber EV, Stock S, Stollenwerk B. Breast cancer attributable costs in Germany: a top-down approach based on sickness funds data. PLoS One. 2012:e51312. Gruber EV, Stock S, Stollenwerk B. Breast cancer attributable costs in Germany: a top-down approach based on sickness funds data. PLoS One. 2012:e51312.
13.
go back to reference Kozierkiewicz A, Topór-Mądry R, Śliwczyński A, Pakulski M, Jassem J, Skuteczność i. Koszty leczenia raka piersi w Polsce; podejście regionalne [effectiveness and costs of breast cancer therapy in Poland: a regional approach]. Nowotwory. 2014;64:24–32.CrossRef Kozierkiewicz A, Topór-Mądry R, Śliwczyński A, Pakulski M, Jassem J, Skuteczność i. Koszty leczenia raka piersi w Polsce; podejście regionalne [effectiveness and costs of breast cancer therapy in Poland: a regional approach]. Nowotwory. 2014;64:24–32.CrossRef
14.
go back to reference Ivanauskienė R, Domeikienė A, Kregždytė R, Milašauskienė Ž, Padaiga Ž. The cost of newly diagnosed breast cancer in Lithuania, 2011. Medicina. 2015;51:63–8.CrossRefPubMed Ivanauskienė R, Domeikienė A, Kregždytė R, Milašauskienė Ž, Padaiga Ž. The cost of newly diagnosed breast cancer in Lithuania, 2011. Medicina. 2015;51:63–8.CrossRefPubMed
15.
go back to reference Oliva J, Lobo F, Lopez-Bastida J, Zozaya N, Romay R. Indirect costs of cervical and breast cancers in Spain. Eur J Health Econ. 2005;6:309–13.CrossRefPubMed Oliva J, Lobo F, Lopez-Bastida J, Zozaya N, Romay R. Indirect costs of cervical and breast cancers in Spain. Eur J Health Econ. 2005;6:309–13.CrossRefPubMed
16.
go back to reference Ivanauskienė R, Padaiga Ž, Vanagas G, Juozaitytė E. Indirect costs of breast cancer in Lithuania in 2008, Pol. Ann Med. 2010;171:25–35. Ivanauskienė R, Padaiga Ž, Vanagas G, Juozaitytė E. Indirect costs of breast cancer in Lithuania in 2008, Pol. Ann Med. 2010;171:25–35.
17.
go back to reference Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies: a review of current methods. PharmacoEconomics. 2006;24:869–90.CrossRefPubMed Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies: a review of current methods. PharmacoEconomics. 2006;24:869–90.CrossRefPubMed
18.
go back to reference Daroudi R, Akbari Sari A, Hahvijou A, Kalaghchi B, Najafi M, Zendehdel K. The economic burden of breast cancer in Iran. Iran J Public Health. 2015;44:1225–33.PubMedPubMedCentral Daroudi R, Akbari Sari A, Hahvijou A, Kalaghchi B, Najafi M, Zendehdel K. The economic burden of breast cancer in Iran. Iran J Public Health. 2015;44:1225–33.PubMedPubMedCentral
19.
go back to reference Kim YA, IH O, Yoon SJ, Kim HJ, Seo HY, Kim EJ, Lee YH, Jung JH. The economic burden of breast cancer in Korea from 2007-2010. Cancer Res Treat. 2015;47:583–90.CrossRefPubMedPubMedCentral Kim YA, IH O, Yoon SJ, Kim HJ, Seo HY, Kim EJ, Lee YH, Jung JH. The economic burden of breast cancer in Korea from 2007-2010. Cancer Res Treat. 2015;47:583–90.CrossRefPubMedPubMedCentral
20.
go back to reference Broekx S, Den Hond E, Torfs R, Remacle A, Mertens R, D’Hooghe T, Neven P, Christiaens M-R, Simoens S. The costs of breast cancer prior to and following diagnosis. Eur J Health Econ. 2011;12:311–7.CrossRefPubMed Broekx S, Den Hond E, Torfs R, Remacle A, Mertens R, D’Hooghe T, Neven P, Christiaens M-R, Simoens S. The costs of breast cancer prior to and following diagnosis. Eur J Health Econ. 2011;12:311–7.CrossRefPubMed
21.
go back to reference Lidgren M, Wilking N, Jönsson B. Cost of breast cancer in Sweden in 2002. Eur J Health Econ. 2007;8:5–15.CrossRefPubMed Lidgren M, Wilking N, Jönsson B. Cost of breast cancer in Sweden in 2002. Eur J Health Econ. 2007;8:5–15.CrossRefPubMed
22.
go back to reference Matsumoto K, Haga K, Kitazawa T, Seto K, Fujita S, Hasegawa T. Cost of illness of breast cancer in Japan: trends and future projections. BMC Res Notes. 2015;8:539.CrossRefPubMedPubMedCentral Matsumoto K, Haga K, Kitazawa T, Seto K, Fujita S, Hasegawa T. Cost of illness of breast cancer in Japan: trends and future projections. BMC Res Notes. 2015;8:539.CrossRefPubMedPubMedCentral
23.
go back to reference Max W, Sung HY, Stark B. The economic burden of breast cancer in California. Breast Cancer Res Treat. 2009;116:201–7.CrossRefPubMed Max W, Sung HY, Stark B. The economic burden of breast cancer in California. Breast Cancer Res Treat. 2009;116:201–7.CrossRefPubMed
24.
go back to reference EY. Metodyka pomiaru kosztów pośrednich w polskim systemie ochrony zdrowia [methodology of estimating indirect costs in polish health care system]. Warsaw: EY; 2013. EY. Metodyka pomiaru kosztów pośrednich w polskim systemie ochrony zdrowia [methodology of estimating indirect costs in polish health care system]. Warsaw: EY; 2013.
25.
go back to reference Havik K, Mc Morrow K, Orlandi F, Planas C, Raciborski R, Röger W, Rossi A, Thum-Thysen A, Vandermeulen V. The production function methodology for calculating potential growth rates & output gaps. Economic papers 535. Brussels: European Commission; 2014. Havik K, Mc Morrow K, Orlandi F, Planas C, Raciborski R, Röger W, Rossi A, Thum-Thysen A, Vandermeulen V. The production function methodology for calculating potential growth rates & output gaps. Economic papers 535. Brussels: European Commission; 2014.
27.
go back to reference Bradley CJ, Bednarek HL, Neumark D. Breast cancer survival, work, and earnings. J Health Econ. 2002;21:757–79.CrossRefPubMed Bradley CJ, Bednarek HL, Neumark D. Breast cancer survival, work, and earnings. J Health Econ. 2002;21:757–79.CrossRefPubMed
28.
go back to reference Bouknight RR, Bradley CJ, Luo Z. Correlates of return to work for breast cancer survivors. J Clin Oncol. 2008;24:345–53.CrossRef Bouknight RR, Bradley CJ, Luo Z. Correlates of return to work for breast cancer survivors. J Clin Oncol. 2008;24:345–53.CrossRef
29.
go back to reference Didkowska J, Wojciechowska U. Liczba chorych na nowotwory złośliwe w Polsce w 2006 roku - chorobowość 5-letnia [number of patients with diagnosed malignant diseases in Poland in 2006 – 5-year prevalence]. Nowotwory. 2011;61:332–5. Didkowska J, Wojciechowska U. Liczba chorych na nowotwory złośliwe w Polsce w 2006 roku - chorobowość 5-letnia [number of patients with diagnosed malignant diseases in Poland in 2006 – 5-year prevalence]. Nowotwory. 2011;61:332–5.
30.
go back to reference Wojciechowska U, Didkowska J, Zatoński W. Cancer in Poland in 2012. Warsaw: the M. Skłodowska-curie memorial cancer center and institute of. Oncology. 2014; Wojciechowska U, Didkowska J, Zatoński W. Cancer in Poland in 2012. Warsaw: the M. Skłodowska-curie memorial cancer center and institute of. Oncology. 2014;
31.
go back to reference Frederix GW, Quadri N, Hövels AM, van de Wetering FT, Tamminga H, Schellens JH, Lloyd AJ. Utility and work productivity data for economic evaluation of breast cancer therapies in the Netherlands and Sweden. Clin Ther. 2013;35:e1–7.CrossRefPubMed Frederix GW, Quadri N, Hövels AM, van de Wetering FT, Tamminga H, Schellens JH, Lloyd AJ. Utility and work productivity data for economic evaluation of breast cancer therapies in the Netherlands and Sweden. Clin Ther. 2013;35:e1–7.CrossRefPubMed
32.
go back to reference Cleeland CS, Mayer M, Dreyer NA, Yim YM, Yu E, Su Z, Mun Y, Sloan JA, Kaufman PA. Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: results from a substudy of the VIRGO observational cohort study. Breast. 2014;23:763–9.CrossRefPubMed Cleeland CS, Mayer M, Dreyer NA, Yim YM, Yu E, Su Z, Mun Y, Sloan JA, Kaufman PA. Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: results from a substudy of the VIRGO observational cohort study. Breast. 2014;23:763–9.CrossRefPubMed
33.
go back to reference Tachi T, Teramachi H, Tanaka K, Asano S, Osawa T, Kawashima A, Hori A, Yasuda M, Mizui T, Nakada T, Noguchi Y, Tsuchiya T, Goto C. The impact of side effects from outpatient chemotherapy on presenteeism in breast cancer patients: a prospective analysis. Spring. 2016;5:327.CrossRef Tachi T, Teramachi H, Tanaka K, Asano S, Osawa T, Kawashima A, Hori A, Yasuda M, Mizui T, Nakada T, Noguchi Y, Tsuchiya T, Goto C. The impact of side effects from outpatient chemotherapy on presenteeism in breast cancer patients: a prospective analysis. Spring. 2016;5:327.CrossRef
34.
go back to reference Macioch T, Hermanowski T. Koszty pośrednie chorób nowotworowych w Polsce w 2009 r. [indirect costs of oncological diseases in Poland in 2009]. In: Hermanowski T, editor. Szacowanie kosztów społecznych choroby i wpływu stanu zdrowia na aktywność zawodową i wydajność pracy [estimation of social costs of disease and health status impact on economic activity and work productivity]. Warsaw: Wolters Kluwer Business; 2013. p. 181–211. Macioch T, Hermanowski T. Koszty pośrednie chorób nowotworowych w Polsce w 2009 r. [indirect costs of oncological diseases in Poland in 2009]. In: Hermanowski T, editor. Szacowanie kosztów społecznych choroby i wpływu stanu zdrowia na aktywność zawodową i wydajność pracy [estimation of social costs of disease and health status impact on economic activity and work productivity]. Warsaw: Wolters Kluwer Business; 2013. p. 181–211.
35.
go back to reference Wytyczne oceny technologii medycznych. Health technology assessment guidelines. Warsaw: Agencja Oceny Technologii Medycznych i Taryfikacji; 2016. Wytyczne oceny technologii medycznych. Health technology assessment guidelines. Warsaw: Agencja Oceny Technologii Medycznych i Taryfikacji; 2016.
36.
go back to reference European Commission. The 2015 aging report, underlying assumptions and projection methodologies, the European economy series, 8/2014. European Commission: Brussels; 2014. European Commission. The 2015 aging report, underlying assumptions and projection methodologies, the European economy series, 8/2014. European Commission: Brussels; 2014.
37.
go back to reference Mazanec SR, Daly BJ, Douglas SL, Lipson AR. Work productivity and health of informal caregivers of persons with advanced cancer. Res Nurs Health. 2011;34:483–95.CrossRefPubMedPubMedCentral Mazanec SR, Daly BJ, Douglas SL, Lipson AR. Work productivity and health of informal caregivers of persons with advanced cancer. Res Nurs Health. 2011;34:483–95.CrossRefPubMedPubMedCentral
38.
go back to reference Mori A, Goren A, Gilloteau I, DiBonaventura MD. Quantifying the burden of caregiving for patients with cancer in Europe. Ann Oncol. 2012;23(suppl 9):ixe25–6. Mori A, Goren A, Gilloteau I, DiBonaventura MD. Quantifying the burden of caregiving for patients with cancer in Europe. Ann Oncol. 2012;23(suppl 9):ixe25–6.
39.
go back to reference Kostrzewski L. Coraz trudniej o rentę [it is more difficult to get a disability pension]. Gazeta Wyborcza. March 2015:31. Kostrzewski L. Coraz trudniej o rentę [it is more difficult to get a disability pension]. Gazeta Wyborcza. March 2015:31.
40.
go back to reference Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med. 1992;34:1005–10.CrossRefPubMed Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med. 1992;34:1005–10.CrossRefPubMed
41.
go back to reference Tarricone R. Cost-of-illness analysis: what room in health economics? Health Policy. 2006;77:51–63.CrossRefPubMed Tarricone R. Cost-of-illness analysis: what room in health economics? Health Policy. 2006;77:51–63.CrossRefPubMed
42.
go back to reference Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: past, present, future. PharmacoEconomics. 2013;31:537–49.CrossRefPubMed Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: past, present, future. PharmacoEconomics. 2013;31:537–49.CrossRefPubMed
Metadata
Title
Productivity losses and public finance burden attributable to breast cancer in Poland, 2010–2014
Authors
Błażej Łyszczarz
Ewelina Nojszewska
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3669-7

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine